Overview

• The global Phase 2b REZOLVE-AD trial met its primary and key secondary endpoints in 393 adults and adolescents following three subcutaneous doses over 16 weeks.
• High- and mid-dose cohorts achieved average EASI score improvements of 61% and 58% compared with 31% for placebo, and up to 46% of patients reached EASI-75.
• Up to 42% of participants reported a clinically meaningful four-point reduction in itch severity with no rise in conjunctivitis, oral ulcers or herpes infections.
• Rezpegaldesleukin was well tolerated overall, with mild injection site reactions as the most frequent side effect and rare serious adverse events.
• Shares climbed 150% and the therapy is projected to exceed $2 billion in peak sales, elevating Nektar’s acquisition appeal for larger pharmaceutical firms.